Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Are there any trials looking at alternative treatments for patients who otherwise would receive 2 years of ADT but have the HSD3B1 gene (homozygous vs heterozygous)?
Related Questions
Would you offer neoadjuvant chemotherapy prior to trimodality therapy in a fit patient who refuses surgery for muscle-invasive bladder cancer?
Would you be more inclined to offer adjuvant therapy to a patient who is age>60 with stage 1B seminoma?
Would you consider adjuvant chemotherapy for high-grade node-positive medullary renal cell cancer after complete resection with negative margins?
Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
How would you approach patients with high-risk localized prostate cancer (per STAMPEDE criteria) receiving RT and concurrent ADT but are unable to tolerate abiraterone secondary to toxicities?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
